The Allay trial at ACC08

April 15, 2008
During the Annual American College of Cardiology 2008 Scientific Sessions, (ACC 08) held in Chicago in March, another successful study, the ALLAY Trial, was presented. A+ Science has been responsible for the ECG handling and coding of all ALLAY ECGs.

The ALLAY* Trial a 36 week randomized, double-blind, multi-center, parallel group trial was designed to compare the efficacy and safety of Aliskiren. The trial compared whether Aliskiren alone or in combination with Losartan compared to Losartan would lead to regression of left ventricular hypertrophy (LVH) evaluated with Magnetic Resonance Imaging (MRI), in overweight patients with essential hypertension. ALLAY is the largest study on regression of LVH evaluated with MRI. A total of 466 patients were randomized from seven countries; Argentina, Colombia, Finland, Italy, Russia, Spain and Sweden.

The ALLAY Trial shows that Aliskiren, the direct renin inhibitor, alone reduces LVH as effectively as current standard treatment with Losartan.

Björn Dahlöf (MD PhD), Scientific and Medical Adviser at A+ Science, has had a major role in designing the ALLAY Trial. His experience and his involvement within several major endpoint trials requiring ECG readings, such as LIFE, ASCOT and recently ACCOMPLISH, led to ECG coding for LVH be an integral part of the ALLAY Trial objectives.

A+ Science in collaboration with the ECG Core Laboratory at Sahlgrenska University Hospital/Östra, has been responsible for the ECG handling and coding of all ALLAY ECGs. A total of 2 333 ECGs were handled by A+ Science in the ALLAY Trial.

A+ Science has been involved with several major multinational trials and has handled and evaluated tens of thousands of ECGs. The company has many years of experience managing both small and large cardiovascular trials and is known for its extensive cardiovascular expertise and its broad investigator network.

April 15, 2008
A+ Science AB

For further information please read the press release from Novartis (opens in new window).

For more information from A+ Science:
Agneta Gelin Friberg, Project Manager ALLAY, +46 (0)31 703 18 68
Pirkko Sulila, Senior Vice President Marketing, Sales and Business Development, +46 (0)8 564 882 42

*ALLAY -ALiskiren in Left VentriculAr HypertrophY

Return to news list